Neurotoxicity
Value of MRI, lumbar puncture questioned for immune cell-associated neurotoxicity syndrome
MRIs and lumbar punctures may not provide enough therapeutic value to be standard-of-care diagnostic tests in patients suffering neurologic symptoms following chimeric antigen receptor T-cell therapy.
Neurodegenerative biomarker may predict CAR T-cell therapy-related neurotoxicity
A blood test may predict which patients are predisposed to developing treatment-related neurotoxicity after chimeric antigen receptor T-cell therapy infusion, according to researchers.
CAR T-cell therapy-related neurotoxicity linked to low blood phosphate levels
Researchers have discovered a link between neurotoxicity related to chimeric antigen receptor T-cell therapy and development of subsequent hypophosphatemia.
Neurologic adverse events manageable after CAR-T in multiple myeloma
Getting to the heart of CAR T-cell therapy’s cardiovascular risks
How much risk is too much? It depends on what is at stake.
CAR-T plus pembrolizumab shows ‘superior’ safety, promising responses in advanced lymphoma
No patients who received pembrolizumab with a CD19/CD22-directed chimeric antigen receptor T-cell therapy experienced high-grade cytokine release syndrome, according to phase 1 study findings presented during ESMO Virtual Congress 2020.
Limiting severe toxicity, mortality after CAR T-cell therapy
In this installment of In Practice, Marco L. Davila, MD, PhD, and Rawan G. Faramand, MD, of H. Lee Moffitt Cancer Center and Research Institute in Tampa, discuss the importance of developing a patient-specific management strategy to limit severe toxicities and mortality after chimeric antigen receptor T-cell therapy.
Neurotoxicity after CAR T-cell therapy has no effect on survival in lymphoma subset
Development of immune effector cell-associated neurotoxicity syndrome did not negatively affect survival outcomes among patients treated with axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma, study results showed.
Researchers develop tool to predict CAR T-cell therapy-associated neurotoxicity
A new prognostic tool has been developed to help clinicians predict which patients may experience neurotoxic effects of chimeric antigen receptor T-cell therapy, according to a study published in JAMA Neurology.
NCCN patient guidelines provide ‘basic understanding’ of CAR T-cell therapy toxicities
The National Comprehensive Cancer Network published the latest in its series of guidelines intended to inform patients and their caregivers about adverse events associated with cancer therapies.